Arcus Biosciences to Host Conference Call to Discuss Fourth-Quarter and Full-Year 2023 Financial Results and Pipeline Updates

Rhea-AI Summary

Arcus Biosciences (NYSE:RCUS) will host a conference call and webcast to discuss pipeline updates and financial results for the quarter and year ended December 31st, 2023. The event will take place on February 21, 2024, at 2:00 PM PT / 5:00 PM ET. Investors can listen to the conference call by dialing (404) 975-4839 (local) or (833) 470-1428 (toll-free) using Access Code: 235272. The live webcast and slide presentation will be available on the company's website at www.arcusbio.com, with a replay available after the event.

HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will host a conference call and webcast on Wednesday, February 21, 2024 at 2:00 PM PT / 5:00 PM ET to discuss pipeline updates and details of the Company’s financial results for the quarter and year ended December 31^st, 2023.

Investors interested in listening to the conference call may do so by dialing (404) 975-4839 (local) or (833) 470-1428 (toll-free), using Access Code: 235272. To access the live webcast and accompanying slide presentation, please visit the “Investors & Media” section of the Arcus Biosciences website at www.arcusbio.com. A replay of the webcast will be available following the live event.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of multiple investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 and dual A2a/A2b receptor), HIF-2a, CD39 and AXL. For more information about Arcus Biosciences’ clinical and preclinical programs, please visit www.arcusbio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240207640939/en/

Media Inquiries

Holli Kolkey

VP of Corporate Communications

(650) 922-1269

hkolkey@arcusbio.com

Investor Inquiries

Pia Eaves

Head of Investor Relations & Strategy

(617) 459-2006

peaves@arcusbio.com

Source: Arcus Biosciences

FAQ

When will the conference call and webcast take place for Arcus Biosciences (NYSE:RCUS)?

The conference call and webcast will take place on February 21, 2024, at 2:00 PM PT / 5:00 PM ET.

How can investors listen to the conference call for Arcus Biosciences (NYSE:RCUS)?

Investors can listen to the conference call by dialing (404) 975-4839 (local) or (833) 470-1428 (toll-free) using Access Code: 235272.

Where can investors access the live webcast and slide presentation for Arcus Biosciences (NYSE:RCUS)?

The live webcast and slide presentation will be available on the company's website at www.arcusbio.com.

Will a replay of the webcast be available for Arcus Biosciences (NYSE:RCUS)?

Yes, a replay of the webcast will be available following the live event.